PEACE-1 long-term update at #ESMO2026 (median FU 7.7y): • Abiraterone + SOC: OS HR 0.75 • Triplet (ADT+doc+abi) vs doublet: mOS 6.2 vs 4.4y, HR 0.68; 8y OS 40% vs 27% • Benefit reg

Kenrick Ng· @Kenrickng1 · X·2026-10-24 18:48· 22 小时前评分70

正文 · 原文

PEACE-1 long-term update at #ESMO2026 (median FU 7.7y): • Abiraterone + SOC: OS HR 0.75 • Triplet (ADT+doc+abi) vs doublet: mOS 6.2 vs 4.4y, HR 0.68; 8y OS 40% vs 27% • Benefit regardless of volume (interaction p=0.56) • High volume: 8y OS 38% vs 20% #ProstateCancer 1/2

8 浏览 · 0 赞 · 0 转发 · 1 回复

帖内回复

Kenrick Ng@Kenrickng1
But 4 yrs on, maybe the debate isn't doublet vs triplet. It's what we do with poor responders. PSA >0.2 at ~6 months = major unmet need & opportunity. Good to see trials now focused here (PEACE-6 PR, TRIPLE-SWITCH, REINFORCE, EvoPAR-PR05), as Ursula Vogl discussed. #ESMO2026 2/2

来源：Kenrick Ng · x.com